Morepen Laboratories Limited · NSE:MOREPENLAB
Morepen Laboratories — Q4 FY2025 Earnings Presentation
54 slides from Morepen Laboratories's earnings presentation, May 12, 2025
Slide 1: Exchange intimation letter: Investor Presentation Q4 FY25
Date: 12/05/2025 To, National Stock Exchange of India Ltd. BSE Limited Exchange Plaza, Bandra Kurla Complex, Phiroze Jeejeebhoy Towers, Bandra (East), Mumbai- 400 051 Dalal Street, Mumbai- 400 001 Symbol: MOREPENLAB Scrip Code: 500288 Subject: Investor Presentation – Q4’ FY25 Dear Sir/ Madam, Please
Slide 2: Q4 FY25 Investor Presentation
Q4'Fy25 investor presentation MOREPEN LABORATORIES LIMITED
Slide 3: Safe Harbour
SAFE HARBOUR This investor presentation has been prepared for general information purposes in respect of Morepen Laboratories Limited (“Company”) together with its subsidiary, as applicable (together, with the Company, the “Group”) only, without regard to any specific objectives, suitability, financ
Slide 4: Executive Summary
Dr. Morepen® EXECUTIVE SUMMARY FY 25
Slide 5: Executive Summary: Business Segments
1 Executive Summary Business Segments: Pharma Business Medical Devices API+Rx+ConsumeR Point of Care 73% 27% Share of Pharma Share of Medical Business Devices FY 25
Slide 6: Executive Summary: Company Positioning
1 Executive Summary: Company Positioning: #1 80 72% commitment & Market leaders In Exporting to over 80 Revenue share of API credibility 6 APis countries from export #1 Rx Market leaders in fully integrated mfg. Increasing share of Strong portfolio of Gluco and BP meters for medical devices Formulat
Slide 7: Executive Summary: Consolidated Revenue
1 Executive Summary consolidated revenue: Annual Revenue quarterly Revenue Rs. in Crores Rs. in Crores 2000 1830 1704 500 470 7.4% 427 10.1% 1500 400 1000 300 200 500 100 0 0 FY'24 FY'25 Q4'FY24 Q4'FY25 FY 25
Slide 8: Pharma Business
Dr. Morepen® PHaRMa BUSINESS FY 25
Slide 9: Pharma Business: API & Forward Integration
2 pHarma Business API & Forward integration: --- API Rx Consumer - b2B Business Medicines health ) l V 73% 27% Share of Pharma Share of Medical Business Devices FY 25
Slide 10: Pharma Business: Total Pharma Revenue
2 Pharma Business Total Pharma revenue : Annual Revenue quarterly Revenue Rs. in Crores Rs. in Crores 400 368 1400 1334 1261 5.8% 338 1200 8.5% 300 1000 800 200 600 400 100 200 0 0 FY'24 FY'25 Q4'FY24 Q4'FY25 FY 25
Slide 11: Pharma Business/API: Market Leadership
2 pHarma Business/API market leadership: ProDuct Rank Export* share PRODUCT share Others Loratadine #1 81% 12.4% Monte 22.8% Rosu DesLoratadine #1 66% 12.3% Montelukast #1 77% Fexo FY25 9.3% Atorvastatin #4 30% Lorata +Des Atorva 23.9% Rosuvastatin #4 30% 19.2% Fexofenadine #3 30% API revenue split
Slide 12: API: New Products Launched
2 pHarma Business/API New products launched*: Diabetics cardiac Other • Sitagliptin • Apixaban • resmetirom • Linagliptin • Edoxaban • Vonoprazan • Dapagliflozin • rivaroxaban • Vortioxetine • Empagliflozin • Olmesartan • bexpiprazole • SAXAGLIPTIN • ticagrelor • Ertugliflozin • bempedoic acid FY 25
Slide 13: API: Product Pipeline
2 pHarma Business/API product pipeline*: Pilot scale u/ Devlopment • Baricitinib • Cenobamate • Tafamidis • Lisdexamfetamine (LDF) • Bilastine • Mavacamten • Finerenone • Vibegron • Rupatadine • Upadacitinib • Cariprazine • Fezolinetant FY 25 *Not available for sales in the countries with valid pate
Slide 14: API: New Products Revenue
2 pHarma Business/API new products: Revenue Share New Product Revenue 120 Rs. in Crores 114 14 12.3% 100 12 10.9% 80 89 10 8.1% 74 8% 60 69 8 6 40 4 20 2 0 0 FY22 FY23 FY24 FY25 FY22 FY23 FY24 FY25 4.2% 65% Increase in Revenue Increase in new products FY 25 contribution over 3 years Revenue over 3 y
Slide 15: API: Increasing Focus on Export
2 pHarma Business/API increasing focus on export Export Share (API) Export Revenue Rs. in Crores 700 72.1% 697 700 67.5% 600 636 600 64.5% 68.63 500 553 556 500 400 400 300 300 200 200 100 100 0 0 FY22 FY23 FY24 FY25 FY22 FY23 FY24 FY25 7.6% 26% Increase in export Increase in export FY 25 contributi
Slide 16: API: Strong Export Network
2 pHarma Business/API Strong Export network: Continent-wise share 80 500 S. America USA Exporting to over 80 top Notch cusotmers 3.4% 15.8% countries worldwide India 27.5% FY25 Europe 60% MENA 2.9% 22.6% Business comes from Experienced sales repeat cusotmers team for all regions Asia 27.9% FY 25
Slide 17: API: Region-wise Performance
2 pHarma Business/API region wise performance: Rs. in Crores USA Europe India* APAC MENA & other 154 152 217 320 268 63 60 292 246 172 FY’24 FY25 FY’24 FY25 FY’24 FY25 FY’24 FY25 FY’24 FY25 FY *Including other income 25
Slide 18: API Revenue
2 Pharma Business/API API revenue : Annual Revenue quarterly Revenue Rs. in Crores Rs. in Crores 956 989 300 278 1000 267 3.5% 4% 250 800 200 600 150 400 100 200 50 0 0 FY'24 FY'25 Q4'FY24 Q4'FY25 FY 25
Slide 19: API: Increasing Sales Volumes
2 Pharma Business/API Increasing sales volumes : Sales Quantity (MT) Average Sales price (INR) Revenue* (Rs in crores) 1000 500 30000 26839 956 989 476 25000 800 828 400 22105 424 20310 20000 600 300 304 15000 400 200 10000 100 200 5000 0 0 0 FY23 FY24 FY25 FY23 FY24 FY25 FY23 FY24 FY25 57% -24% 19%
Slide 20: Installed API Capacity
2 Pharma Business/API Installed API Capacity: caPAcities FY23 FY24 FY25 314 KL 403 KL 514 KL Planned for FY26 600 KL 91% UP FY 25
Slide 21: Intellectual Property
2Pharma Business/ API Intellectual Property: 168 55 325 27 worldwide Patents R&D scientists in Drug master files US DMFs and Europe filed the r&D Lab worldwide CEPs 48 NIL 30 New Molecules ‘483’ observation* for last New Rx products Enhanced chemistry Developed three USFDA inspections developed and
Slide 22: Regulatory Approvals
2Pharma Business/API Regulatory Approvals: I I JAPAN ANVISA United States Europe Japan Brazil MFDS 'KOREA China Korea India WHO GMP iso 13485 (Med Devices) FY 25
Slide 23: Rx & OTC: Increased Focus on B2C
2 pHarma Business/RX & OTC Increased focus oN B2C Rs. in Crores 350 344 29% 300 305 250 276 Increase in Revenue in 200 Q4'FY25 150 100 21% 50 0 FY23 FY24 FY25 Increase in Formulation Revenue in 2 years FY 25
Slide 24: Adding 1000 Medical Representatives in 3 Years
2 pHarma Business/RX & OTC To Add 1000 Medical representatives in 3 years No. of Medical representatives 1200 200 1000 800 1200 Medical Representatives as on March 2025 750 600 I 400 400 400 200 200 Medical Representatives 0 Mar'25 Mar'26 Mar'27 Mar'28 planned by March 26 FY 25
Slide 25: First Time in India: Resmetirom
2 pHarma Business/RX & OTC First time in India- Restemtirom • Developed in-house by the Morepen R&D Team • Got CDSCO Approval for - 'Tlie Joy Of <;;rowing <Together conducting Bio Studies "Among the first few companies • Getting ready to in India getting ready for the conduct Bioequivalence studies
Slide 26: Top Rx Products
2 pHarma Business/RX & OTC top Rx Products Anti infective '. GastroIntestinal NEW ' '. NEW ~ lnte UdoFix ,~v ~ AciFix,;@i•>> SUSPENSION Multi vitamin Cardio Diabetic ✓ NEW • Ticap. . .e. .---n® ApixamoreENEYl EmpamoreM•EW • FY 25
Slide 27: Top OTC Products (Trade)
2 pHarma Business/RX & OTC top OTC Products (TRade) ~ orepen~ »,,._ ~ LC!molatc:" plus Burnol Lemolate Pain-X Sexual Wellness - ,i;:"t11o(e'fle ~ . ~ ~ orepen., Actives MMJtl'I UtcerGe Acidity X Oral Health ORS Range Fever-x FY 25
Slide 28: Top OTC Products (Online)
2 pHarma Business/RX & OTC top OTC Products (online) 00 Dr. Morepen• Lightlife® 1 D, M~epeo OO 1 3&1• su1tah,,b,.W1l9hlM1nagem1n1 Lightlife _ _. . w,tlgO,.........- Weight Mangement Omega-3 Sexuall Wellness Sexual Wellness Skin Collagen Multivitamins Cod Liver Biotin FY 25
Slide 29: Top OTC Products (Nutrition)
2 pHarma Business/RX & OTC top OTC Products (Nutrition) whey Protein Turbo Whey Protien Pre WorkOut Raptor Isotonic EAA +BCAA FY 25
Slide 30: Medical Devices
Dr. Morepen® MeDICaL DEVICES FY 25
Slide 31: Medical Devices: Market Leadership
3 Medical Devices market leadership: #1 #1 25 yr Market Leaders for Market Leaders for of focused customer Own manufacturing Blood Glucose meters BP Monitors service since 10 years 14m ISO 14 million Meters installed, fully backward integrated All India Distribution ISO-13485 Approved repeat custome
Slide 32: Top Selling Products
3 Medical Devices Top selling Products: Blood Glucose meters BP Monitors Nebulisers Thermometers Ortho supports Stethoscope Pregnancy Kits FY 25
Slide 33: Medical Devices: Total Revenue
3 Medical Devices Total revenue : Annual Revenue quarterly Revenue Rs. in Crores Rs. in Crores 496 120 500 103 443 12% 100 89 400 15% 80 300 60 200 40 100 20 0 0 FY'24 FY'25 Q4'FY24 Q4'FY25 FY . 25
Slide 34: Glucometer Revenue
3 Medical Devices glucometer revenue : ,,,,, 11..ID mg/dL Annual Revenue Rs. in Crores cumulative no. of strips 400 387 ,... meter base sold UJ./' ' (millions) 342 13% (millions) 20 500 300 14.2 414 15 400 359 15% 11.7 21% 200 10 300 200 100 5 100 0 0 0 Mar'24 Mar'25 FY24 FY25 FY'24 FY'25 FY 25
Slide 35: BP Monitor Revenue
3 Medical Devices BP Monitor revenue : no. of BP meters sold Annual Revenue (millions) Rs. in Crores 100 91 1.17 1.2 14% 1.05 80 12% 80 1.0 0.8 60 0.6 40 0.4 0.2 20 / 0.0 0 FY'24 FY'25 FY'24 FY'25 FY 25
Slide 36: Capacity Expansion
3 Medical Devices Capacity Expansion: No. of Units Per annum Glucometers Gluco Test Strips BP MOnitors (millions) (millions) (millions) 40 3.60 600 2.0 1.80 600 500 424 1.5 30 2.51 400 0.91 20 300 1.0 200 0.5 10 100 0 0 0.0 Present Planned Present Planned Present Planned FY 25
Slide 37: Growth Drivers
3 Medical Devices growth drivers: - --- -- Increasing Health Growing Health Higher disposable Advanced products Awareness concerns income and treatments $234bn 12.7% 212m 62% Global Medical Devices CAGR Growth RAte Highest diabetic remain undiagnosed Market by 2032 Population in India and untreated
Slide 38: Digital Moves
3 Medical Devices Digital Moves: ....... _ H O U • l'l'NQ'J Your Total Logs Uilolftowo'"'.:c.l i :!0« ;, l0_; £ Take control of your - ■ 24 10 16 . TDLlllllood Q.,.,,oi.,;LC> Toultllood Prn........ L.-, ToUIWliCN \.c,p health and wellness with r 901 1 ~1 1'1'-'•J • r 0 ~v......,.l l1 HlAC tt YOUfl H
Slide 39: Growth Drivers: International Expansion
3 Medical Devices 95 growth drivers: n,gl dL • Expansion to International markets: ,t;,' •re pen·~- 1 Thailand Qatar Oman • Planning another 2-3 countries in the Middle East, Africa and Asia • Good Progress in the US market long-term supplies with chain stores • Soon launching at Amazon.com (USA) am
Slide 40: Financial Overview
Dr. Morepen® Financial OVERVIEW FY 25
Slide 41: Annual Performance
4 Fiancial Overview Annual Performance: Rs. 2.20 Rs. in Crores Annual EPS- up 17% : Gross Revenue EBITDA PAT 2000 200 120 1830 7.4% 192 11.5% 100 118 22% 1500 1704 150 173 80 97 1000 100 60 10.1% 10.5% 5.7% 6.5% 40 500 50 20 0 0 0 FY'24 FY'25 FY'24 FY'25 FY'24 FY'25
Slide 42: Quarterly Performance
4 Fiancial Overview Quarterly Performance: Rs. in Crores : Gross Revenue EBITDA PAT 500 60 30 400 470 50 25 29 427 10% 53 11% 40 47 20 29% 300 20 30 15 200 12.3% 10.0% 6.72% 4.32% 20 10 100 10 5 0 0 0 Q4'FY24 Q4'FY25 Q4'FY24 Q4'FY25 Q4'FY24 Q4'FY25
Slide 43: Annexures
Dr. Morepen® 5 ANNeXURES FY 25
Slide 44: Regulatory Updates
Regulatory Updates NEW PATENT NEW PATENT FILED FILLED Improved Process fo r the Novel Process for the p repa ration of preparation of ■I Saxag!ir:2tin Resmetirom . ■I An anti-diabetic product, USDMF Used for the treatmen t of adult ■I 33635 & 35690, approved DMF in Taiwan, filed in Saudi Arabia, pat
Slide 45: International Exhibitions (API)
International Exhibitions (API) CPHI MILAn CPHI India CPHI CHINA FCE PHARMA SÃO PAULO ~OPEPEH Pharma Tech CPHI Middle East DCAT WEEK CPHI Japan ~.;;. East Africa New York "()ill l"'1rio/ Excclle,1ce ~ ~ ,l.., .,kt
Slide 46: International Exhibitions (Devices)
VIP I Ollll(j ( ~ Pt c • Ccrllct International Exhibitions (Devices) V ll' I A P1 , , ss1onals STl:TH05COPE -' C ( ( ·-. - G "t Medica- Germany Arab Health - Dubai Global Health - Saudi FY 25
Slide 47: Awards and Recognition
Awards and Recognition Atda.n Top SO Supply Chain & Logistics tN"'"'a,,,dtlOI Mortpt"LabOf~~~es .... li111i1ediodi ,,,.... fl. ELl;<IA W,' Visionary Finance leader Brand icon of the Award 100 supply Entrepreneur 2024 of the year year 2024 chain ~ votive inology Awards2024 ~OPEPEH Best Healthcare ASI
Slide 48: Distribution
Distribution • • : r-7:• + ~~.,.~ : • -~-¥ 614 5.3K 0 343K I : Total Sales force Distributors all retail touch points across across the portfolio over India product portfolio I.M)Al<H IJ\MMU~ KASHMIR ' I , -o- FIVE IIIMACIIAL PltAOESill of r lol C1ANDIGAR I I PUNJAB HARYANA 11'11'TARAIOIAND [21NEWDE
Slide 49: Manufacturing Plants
Manufacturing Plants Facilities at par with international Standards: 9 Baddi (1998) 9 Masulkhana (1984) 9 Parwanoo (1996) 9 Parwanoo (2007) APIs, Med. Devices APIs Products Formulations Formulations Formulations /lOPEPEH ~.;;. -MIil l'ean,;,/ ~ ,l.., .,kt Excclle,1ce ~
Slide 50: Integrated Pharma Complex at Baddi (HP)
erg integrated pharma complex at baddi (HP) INDIA
Slide 51: Leadership Team
sanjay SURI kushal SURI EXecutive director & CEO- API Director-API Sales & MKTG SUSHIL SURI CHairman & Managing Director API- SALES team
Slide 52: Management Team
varun SURI anubhav SURI amita sharma ceo- consumer care ceo-medical devices C0O- API AJAY SHArma cFo SENIOR MANAGEMENT FINANCE TEAm API- SALES team
Slide 53: Senior Management
Vipul Srivastava Vikas Sharma Manju Nath Pyush Tandon Vivan Prashar COmpany Secretary Head Talent Acquisition Chief of R&D (Devices) VP- Sales & Mktg (API) VP- project & ENGG. ashutosh sharma SUMIT BHAtnagar NISHANt DOSHI Sandeep Atri MK Sharma VP- Sales & Mktg (RX) VP-FINANCE & ACC VP- CORP FINANCE
Slide 54: Thank You
Looking Forward to a Fruitful Partnership Thank you MOREPEN LABORATORIES LIMITED
Morepen Laboratories — Q4 FY2025 Earnings Presentation on 6ix